CJC/IPA Protocol (CJC-1295/Ipamorelin)
GHRH/GHRP Combination | Growth Hormone Optimization
Community Research
Join others researching CJC/IPA Protocol — share findings, ask questions, and learn from real experiences
A dual-pathway protocol combining CJC-1295 and Ipamorelin that targets growth hormone secretion through complementary mechanisms. CJC-1295 demonstrates 2-10 fold GH increases with 6-8 day duration, while Ipamorelin provides selective GH release without cortisol elevation.
CJC-1295 activates GHRH receptors via albumin-binding DAC technology for sustained elevation. Ipamorelin selectively activates ghrelin receptors (GHSR1a) without affecting ACTH/cortisol, preserving natural pulsatile GH patterns.
Molecular Data
N/A Complex or non-standard sequence format
Research Indications
Growth hormone elevation supports muscle protein synthesis and nitrogen retention during training.
Sustained GH patterns may accelerate muscle repair between exercise sessions.
GH optimization helps maintain muscle during caloric restriction or aging.
Growth hormone promotes lipolysis while supporting lean tissue maintenance.
Enhanced GH patterns may improve glucose and fat utilization.
Evening GH peaks align with deeper, more restorative sleep patterns.
Sustained GH elevation supports skin elasticity and connective tissue health.
Growth hormone supports tissue repair and recovery from exercise or injury.
Enhanced collagen synthesis supports joint and connective tissue integrity.
Dosing Protocols
Subcutaneous administration optimal for bioavailability; available as blended vials or separate formulations.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| General Health Optimization | 200mcg each (0.2mL if 1mg/mL) | Once daily | SubQ |
| Performance Enhancement | 250mcg each (0.25mL if 1mg/mL) | Once daily | SubQ |
| Recovery Optimization | 300mcg each (0.3mL if 1mg/mL) | Once daily | SubQ |
| Conservative Approach | 150mcg each (0.15mL if 1mg/mL) | 5 days per week | SubQ |
Reconstitution Instructions
- Bacteriostatic water (2-4mL)
- Insulin syringes (0.3-1mL capacity)
- Alcohol swabs for sterilization
- 1 BLENDED: Add 2mL bacteriostatic water to create ~2mg/mL concentration
- 2 SEPARATE: Add 2mL water to each vial for 1mg/mL per peptide
- 3 Draw 0.2-0.3mL for 200-300mcg dosing
- 4 Mix equal volumes or inject at different sites
- 5 Administer 2-3 hours post-meal, 30-60 minutes before bed
- 6 Rotate subcutaneous sites (abdomen, thigh, upper arm) daily
Interactions
What to Expect
Side Effects & Safety
Common Side Effects
- Water retention and joint swelling
- Carpal tunnel syndrome (numbness/tingling)
- Mild blood glucose elevation
- Injection site irritation with improper rotation
Stop Signs - Discontinue if:
- Persistent joint pain or swelling indicating fluid retention
- Significant blood glucose changes or diabetic control issues
- Unusual fatigue, lethargy, or mood deterioration
- Injection site infections or persistent reactions
- Numbness or tingling in hands/feet
- Signs of accelerated tumor growth if cancer history exists
Contraindications
- Cancer history or active malignancy
- Severe diabetes requiring tight glucose control
- Carpal tunnel syndrome or nerve compression disorders
Quality Checklist
Good Signs
- Standard format labeling: '10mg total: 5mg CJC-1295 + 5mg Ipamorelin'
- 1:1 ratio maintenance between peptides for optimal effects
- Clear reconstitution without particles or cloudiness
- Certificate of Analysis with individual peptide purities
- Proper cold chain with cold packs and immediate refrigeration
Warning Signs
- Format selection: Beginners prefer separate vials for tolerance testing
- Blended format offers convenience but limits dose adjustment
- Combination protocols lack peer-reviewed clinical validation
Bad Signs
- Damaged packaging or missing refrigeration
- Heat exposure during shipping
- Lack of Certificate of Analysis documentation
References
- Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adultsTeichman SL, Neale A, Lawrence B, et al.Journal of Clinical Endocrinology & Metabolism (2006)
Single CJC-1295 injection produced dose-dependent 2-10 fold GH increases for 6+ days and 1.5-3 fold IGF-1 increases for 9-11 days; estimated half-life 5.8-8.1 days.
- Ipamorelin, the first selective growth hormone secretagogueRaun K, Hansen BS, Johansen NL, et al.European Journal of Endocrinology (1998)
Ipamorelin is the first GHRP-receptor agonist with selectivity for GH release similar to GHRH; does not release ACTH or cortisol even at doses over 200-fold the ED50 for GH.
- Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analogIonescu M, Frohman LAJournal of Clinical Endocrinology & Metabolism (2006)
CJC-1295 preserves pulsatile GH secretion with unaltered pulse frequency and magnitude; basal GH levels increased 7.5-fold, mean GH 46%, and IGF-1 45%.
- Ghrelin and growth hormone secretagogues potentiate GH-releasing hormone-induced cAMP production in cells expressing transfected GHRH and GH secretagogue receptorsCunha SR, Mayo KEEndocrinology (2002)
GHS potentiate GHRH-induced cAMP in a dose-dependent manner requiring co-expression of both receptors, providing the cellular basis for GHRH/GHRP synergy.
Related Peptides
Disclaimer
This information is for educational and research purposes only. Consult a healthcare professional before use.